Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab

FLIO parameters correlated with visual acuity changes, while retinal thickness did not. This suggests that FLIO may capture treatment-induced alterations beyond structural changes, potentially reflecting metabolic processes. FLIO may therefore serve as a valuable adjunct tool for monitoring anti-VEGF therapy response in neovascular AMD.